Medscape September 28, 2022
By Ahmed Aboulenein

WASHINGTON (Reuters) – U.S. President Joe Biden claimed victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer’s drug.

Biden highlighted a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer. He said the result will be a saving of more than $60 a year per beneficiary.

“It’s going to be a godsend for many families,” Biden told healthcare advocates in a White House Rose Garden event.

“It’s going to...

Today's Sponsors

LEK
Teladoc Health
Amwell

Today's Sponsors

LEK
Teladoc Health

Today's Sponsor

Oliver Wyman

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Insurance, Medicare, Pharma / Biotech, Pricing / Spending
Instead of Drug Spending Caps, Medicare Should Try Value-Based Contracting
Medicare Part D: A First Look at Medicare Drug Plans in 2023
Medicare Drug Price Negotiation: Key Decisions To Reach A “Fair Price”
Addressing Cancer Drug Costs in Medicare Part D
How Should Medicare Negotiate Drug Prices? A Summary of the Options